Michael Makris/LinkedIn
Apr 3, 2026, 15:51
Michael Makris: Approved but Unavailable Hemophilia B Gene Therapy Remains Out of Reach
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”If you are hoping to have gene therapy for hemophilia B you will have to wait, as currently there is no product available for use outside China.
Hemgenix is the only FDA/EMA approved gene therapy that is commercially available, but the company making it has announced that they do not have any product due to a manufacturing issue. They stress that this is not a safety issue.
The Chinese product is only approved for use in China, and it is at least theoretically possible to travel to have the infusion in Shanghai.”
Other posts featuring Michael Makris on Hemostasis Today.
-
Apr 3, 2026, 15:50Saleh Owimer: This Blood Bag is a ‘Ticking Time Bomb’ If It Isn’t Handled Carefully
-
Apr 3, 2026, 15:47Ken Kuang: When Fluid Dynamics Meets Life-Saving Surgery
-
Apr 3, 2026, 14:15Christopher Robinson: Use of Clamps for Hemostasis in Complex Cesarean Delivery
-
Apr 3, 2026, 13:56Cedric Hermans: A New Viewpoint on Rebalancing Coagulation in Haemophilia
-
Apr 3, 2026, 13:44Erin VanDyke: Progress, Partnerships, and Patient Impact in VTE Care
-
Apr 3, 2026, 13:25Tomaz Crochemore: The Future of Medicine is Precision
-
Apr 3, 2026, 13:21Strengthening Care for Bleeding Disorders in Latin America – WFH
-
Apr 3, 2026, 11:44Shiny K. Kajal: The Shift from Number-Based to Patient-Centered Transfusion
-
Apr 3, 2026, 05:59Nathan Connell: How the 2021 VWD Guidelines Are Actually Changing Real – World Practice